Allogene Therapeutics to Report Second Quarter 2024 Financial Results

Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., July 31, 2024 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T cell (CAR T) therapies for cancer, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Monday, August 7, 2024.

Net loss for the first quarter of 2024 was $650 million, or $0.38 per share, including non-cash stock-based compensation expense of $170 million.

Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise.